{"product_id":"alnylam-business-model-canvas","title":"Alnylam Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam Business Model Canvas: RNAi Strategy, Partners \u0026amp; Revenue Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Alnylam's business model—this concise Business Model Canvas breaks down value propositions, key partners, revenue streams, and cost drivers to show how RNAi innovation scales into commercial success; perfect for investors, consultants, and founders seeking actionable, company-specific insights—download the full Word and Excel canvas to benchmark strategy and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam holds high-value alliances with Roche and Regeneron to co-develop and co-commercialize RNAi therapies, sharing late-stage trial costs; combined 2024–25 collaboration revenue and milestones exceeded $1.1 billion, with Roche\/Regeneron-funded R\u0026amp;D covering ~40% of program costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial and Royalty Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam uses non-dilutive financing with partners like Blackstone, securing upfront cash (Blackstone deal provided $1.1bn in 2021 and related financings reached ~$1.7bn through 2024) in return for royalty interests on future sales such as the inclisiran-related economics, preserving equity while funding R\u0026amp;D. This lets Alnylam keep a strong balance sheet (net cash\/marketable securities ~$3.5bn at end-2024) and speed clinical expansion across its RNAi pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam partners with top universities and centers (e.g., MIT, Harvard, Broad Institute) to advance RNAi delivery and discovery; grants and collaborations accounted for ~5% of R\u0026amp;D inputs in 2024, accelerating target ID for its modular platform and adding ~30 peer-reviewed papers from 2020–2024 that bolster clinical credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam partners with specialized contract manufacturing organizations (CMOs) and raw-material suppliers to secure complex oligonucleotides, GalNAc-conjugates, and lipid nanoparticles needed for global launches; in 2024 Alnylam disclosed multi-year CMO agreements supporting projected annual production capacity growth of ~40% to meet demand for ONPATTRO and newer siRNA launches.\u003c\/p\u003e\n\u003cp\u003eMaintaining a diversified supply chain and dual-sourcing strategies is top priority to avoid disruptions and protect patient access to life-saving RNAi medicines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-year CMO deals supporting ~40% capacity growth (2024)\u003c\/li\u003e\n\u003cli\u003eDual sourcing for key raw materials and lipids\u003c\/li\u003e\n\u003cli\u003eCapacity scaling for GalNAc and LNPs ahead of global launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam partners with patient groups for hATTR amyloidosis and acute hepatic porphyria to shape trials, improve enrollment (trial sites reported 15–30% faster recruitment in 2023), and push for reimbursement; these alliances informed value-based contracts tied to outcomes and helped secure \u0026gt;$1.6B in global net product revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eWorking with healthcare systems aligns pricing to care costs and supports outcomes-based agreements, reducing payor objections and enabling broader access in major markets like the US and EU.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient groups: faster recruitment (15–30% in 2023)\u003c\/li\u003e\n\u003cli\u003eReimbursement impact: supports outcomes-based contracts\u003c\/li\u003e\n\u003cli\u003eFinancial scale: \u0026gt;$1.6B net revenue in 2024\u003c\/li\u003e\n\u003cli\u003eFocus: hATTR, acute hepatic porphyria\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam + partners drive $4.4B+ value: $1.1B milestones, $1.7B financing, $1.6B revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam’s key partners (Roche, Regeneron, Blackstone, top CMOs, academic centers, patient groups) supply co-commercialization, non-dilutive cash, R\u0026amp;D, manufacturing scale, and trial\/reimbursement support—together generating \u0026gt;$1.1B collaboration milestones (2024–25), ~$1.7B partner financings (through 2024), net product revenue \u0026gt;$1.6B (2024), and ~40% CMO capacity growth (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024–25 $\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaborations\u003c\/td\u003e\n\u003ctd\u003e1.1B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner financings\u003c\/td\u003e\n\u003ctd\u003e~1.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet rev\u003c\/td\u003e\n\u003ctd\u003e1.6B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Alnylam detailing customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure, and regulatory\/governance considerations to reflect real-world RNAi therapeutics operations and strategic advantages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Alnylam’s RNAi-focused business model with editable cells to quickly identify core components, streamline investor presentations, and save hours of formatting for boardrooms or cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi Platform Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam continually refines its proprietary RNAi delivery platforms—Enhanced Stabilization Chemistry (ESC) and GalNAc conjugates—aiming to boost siRNA potency, durability, and safety to lower dose frequency and adverse events; R\u0026amp;D spend was $1.9B in 2024, 28% of revenue. \u003c\/p\u003e\n\u003cp\u003eTeams optimize chemistry and delivery to expand beyond liver targets into CNS, eye, and lung programs; as of Dec 2025 Alnylam reported 10 clinical-stage programs addressing \u0026gt;8 diseases outside liver. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam runs dozens of global clinical trials across phases I–III, collecting detailed safety and efficacy data and monitoring patients to meet FDA and EMA standards; in 2024 Alnylam reported \u0026gt;1,500 active trial sites and invested $1.1B in R\u0026amp;D for clinical development. Successfully completing these trials remains the primary route to secure marketing approvals and drove product revenues to $2.3B in 2024, underscoring trial execution as central to commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Strategy and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam is scaling commercial operations to support launches and global expansion—Amvuttra and Givlaari drove combined product revenues of $1.12B in 2024, so teams focus on HCP education about RNAi benefits and real-world outcomes to boost uptake.\u003c\/p\u003e\n\u003cp\u003eMarket-access efforts prioritize payer negotiations and value dossiers; Alnylam reported coverage agreements across Europe and the US for \u0026gt;60% of target lives by end-2024, essential to sustain revenue growth and share gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam manages thousands of patents—over 2,500 worldwide as of 2025—to protect foundational RNAi (RNA interference) tech and specific drugs; legal teams both defend these patents and file new claims to cover delivery and formulation advances, preserving a licensing moat that supports royalty and partnership income.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~2,500 patents worldwide (2025)\u003c\/li\u003e\n\u003cli\u003eDefend vs. infringement and inter partes reviews\u003c\/li\u003e\n\u003cli\u003eProtect delivery, chemistry, and indications\u003c\/li\u003e\n\u003cli\u003eEnables licensing and royalty revenue streams\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory affairs at Alnylam keep continuous contact with FDA, EMA and other agencies to secure approvals (e.g., 2024 US approvals and ongoing EU filings) and submit NDAs; teams manage post-marketing surveillance for ~10 approved indications and safety reports tied to ~\\$1.6B 2024 product revenue.\u003c\/p\u003e\n\u003cp\u003eCompliance enforces promotion and clinical practice rules across jurisdictions, maintaining audit readiness and reporting to limit regulatory fines and protect market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous agency liaison: FDA, EMA, PMDA\u003c\/li\u003e\n\u003cli\u003eNDAs and lifecycle submissions\u003c\/li\u003e\n\u003cli\u003ePost-market surveillance for ~10 indications\u003c\/li\u003e\n\u003cli\u003eSupports ~\\$1.6B 2024 product revenue\u003c\/li\u003e\n\u003cli\u003eGlobal promo and clinical compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaling RNAi: Global trials, 2,500 patents, $1.6B–$2.3B revenue push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: advance RNAi delivery (ESC, GalNAc) and expand targets; run global clinical trials to secure approvals; scale commercial, market-access, and payer negotiations; manage ~2,500 patents (2025) and regulatory\/post‑market surveillance supporting ~$1.6B–$2.3B 2024 product revenues.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$1.9B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\u003c\/td\u003e\n\u003ctd\u003e~1,500 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e~2,500 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the actual Alnylam Business Model Canvas—not a mockup or sample—and it exactly matches the file you’ll receive after purchase; upon completing your order you’ll download the full, ready-to-edit document in the same format and layout shown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749708280185,"sku":"alnylam-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alnylam-business-model-canvas.png?v=1772217403","url":"https:\/\/growthsharematrix.com\/products\/alnylam-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}